Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LPTX 
Leap Therapeutics Inc (LPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LPTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.15% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.84M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta -0.22 | 52 Weeks Range 0.22 - 4.79 | Updated Date 06/30/2025 |
52 Weeks Range 0.22 - 4.79 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-02 | When After Market | Estimate -0.58 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -96.05% | Return on Equity (TTM) -203.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -21117547 | Price to Sales(TTM) 160.1 |
Enterprise Value -21117547 | Price to Sales(TTM) 160.1 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 0.47 | Shares Outstanding 41439500 | Shares Floating 32223378 |
Shares Outstanding 41439500 | Shares Floating 32223378 | ||
Percent Insiders 16.2 | Percent Institutions 29.17 |
Analyst Ratings
Rating 1 | Target Price 3 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Leap Therapeutics Inc
Company Overview
History and Background
Leap Therapeutics, Inc., founded in 2011, is a biopharmaceutical company focused on developing targeted immuno-oncology therapeutics.
Core Business Areas
- DKN1-Fc Program: Development of DKN-01, an anti-DKK1 antibody, targeting the DKK1 protein involved in tumor growth and metastasis.
- FLT4 Program: Development of FLT4 inhibitors for oncology applications.
Leadership and Structure
The leadership team includes Douglas E. Onsi, President and CEO. The company operates with a focus on clinical development and partnerships.
Top Products and Market Share
Key Offerings
- DKN-01: DKN-01 is Leap Therapeutics' lead product candidate, an anti-DKK1 antibody being investigated in clinical trials for various solid tumors. There is currently no market share data available for DKN-01 as it is not yet approved. Competitors in similar tumor microenvironment-targeting approaches include companies developing TGF-beta inhibitors and other Wnt pathway modulators.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in oncology, is characterized by high research and development costs, regulatory scrutiny, and intense competition.
Positioning
Leap Therapeutics is a clinical-stage company focusing on novel immuno-oncology targets, aiming to address unmet needs in specific cancer patient populations.
Total Addressable Market (TAM)
The oncology therapeutics market is estimated to be worth billions of dollars. Leap is targeting specific subsets of cancer patients, so its TAM is a fraction of the overall oncology market. Determining the exact value requires detailed clinical trial data and market analysis.
Upturn SWOT Analysis
Strengths
- Novel immuno-oncology target (DKK1)
- Clinical-stage pipeline
- Strategic collaborations
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- No approved products
- High risk of failure in drug development
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Breakthrough Therapy Designation or Fast Track designation from regulatory bodies
Threats
- Clinical trial failures
- Competition from other immuno-oncology therapies
- Regulatory hurdles
- Patent challenges
- Changes in the reimbursement landscape
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- VIRX
Competitive Landscape
Leap Therapeutics competes with companies developing other immuno-oncology therapies and targeted therapies for cancer. Leap's advantage lies in its focus on the DKK1 pathway.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancement of the DKN-01 program through clinical trials.
Future Projections: Future growth is dependent on the success of clinical trials and potential partnerships. Analyst estimates can be found on financial websites.
Recent Initiatives: Recent initiatives include advancing clinical trials for DKN-01 and exploring new indications.
Summary
Leap Therapeutics is a clinical-stage biopharmaceutical company focusing on immuno-oncology. It is relying on the succesful advancement of DKN-01 program. Clinical trial results and securing collaborations are key drivers. The high risk of drug development and strong competition from larger players remain significant challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Leap Therapeutics' SEC filings (10-K, 10-Q)
- Leap Therapeutics' website
- Financial news and data providers
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The biopharmaceutical industry is inherently risky, and investments in companies like Leap Therapeutics carry a high degree of risk. This analysis is based on publicly available information and may not be exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Leap Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2017-01-25 | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director Mr. Douglas E. Onsi J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.leaptx.com |
Full time employees 24 | Website https://www.leaptx.com | ||
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.